ArticleFrontiers in immunology2020
Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Long-term safety and efficacy of BCMA-directed CAR T-cell therapies in multiple myeloma: comparative insights from Cilta-cel, Ide-cel, Anito-cel, and FCARH143.Translational cancer research · 2026Article
- Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab.Blood cancer journal · 2026Article
- Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignancies.Frontiers in immunology · 2026Review
- Vaccination in Multiple Myeloma: Challenges and Strategies.European journal of haematology · 2025Review
- Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Myeloma cell-intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myeloma.HemaSphere · 2024Article
- Benefit delayed immunosenescence by regulating CD4Aging cell · 2024Review
- Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy.Frontiers in oncology · 2024Review
- Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma.Frontiers in oncology · 2024Review
- Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individuals.Clinical & translational immunology · 2024Article
- T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy.Scientific reports · 2022Article
- Article
- TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate.Cancer immunology research · 2022Article
- T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells.Molecular therapy. Methods & clinical development · 2022Article
- Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma.Experimental hematology & oncology · 2022Review
- Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment.Biomolecules · 2022Review
- Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence.Journal of translational medicine · 2021Article
- T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy.Frontiers in immunology · 2021Review
- PD-1 and TIGIT Are Highly Co-Expressed on CD8Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New diagnoses of multiple myeloma (MM) tend to occur after the age of 60, by which time thymic output is severely reduced. As a consequence, lymphocyte recovery after lymphopenia-inducing anti-MM therapies relies on homeostatic proliferation of peripheral T cells rather than replenishment by new thymic emigrants. To assess lymphocyte recovery and phenotype in patients with newly diagnosed MM (NDMM) and relapsed/refractory MM (RRMM), we tracked CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.